News coverage about Digirad (NASDAQ:DRAD) has trended somewhat negative recently, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Digirad earned a coverage optimism score of -0.01 on Accern’s scale. Accern also gave media coverage about the medical equipment provider an impact score of 46.2695744969226 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

DRAD has been the subject of several research reports. B. Riley restated a “buy” rating and issued a $6.00 price target on shares of Digirad in a research note on Thursday, October 5th. TheStreet downgraded shares of Digirad from a “c” rating to a “d+” rating in a research note on Friday, November 3rd. Finally, ValuEngine downgraded shares of Digirad from a “buy” rating to a “hold” rating in a research note on Sunday.

Shares of Digirad (DRAD) remained flat at $$2.60 during mid-day trading on Thursday. The company’s stock had a trading volume of 171,300 shares, compared to its average volume of 228,350. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.44 and a quick ratio of 1.07. The stock has a market cap of $52.14, a price-to-earnings ratio of -4.48 and a beta of 1.89. Digirad has a 1 year low of $1.90 and a 1 year high of $5.68.

Digirad (NASDAQ:DRAD) last issued its earnings results on Friday, November 3rd. The medical equipment provider reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.04. The firm had revenue of $28.56 million during the quarter, compared to the consensus estimate of $31.21 million. Digirad had a negative net margin of 9.93% and a positive return on equity of 9.82%. analysts forecast that Digirad will post 0.09 earnings per share for the current year.

WARNING: “Digirad (DRAD) Earning Somewhat Critical Press Coverage, Report Finds” was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at

About Digirad

Digirad Corporation provides healthcare solutions. The Company’s segments include Diagnostic Services, Mobile Healthcare, Diagnostic Imaging and Medical Device Sales and Services. Through Diagnostic Services, the Company offers an imaging services program as an alternative to purchasing equipment or outsourcing the procedures to another physician or imaging center.

Insider Buying and Selling by Quarter for Digirad (NASDAQ:DRAD)

Receive News & Ratings for Digirad Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Digirad and related companies with's FREE daily email newsletter.